not FDA-approved as of January 2025 Best Phase 2 result / 24.2% mean body weight loss at 48 weeks (12 mg dose, N=338 trial) Extended estimate / 28.7% mean weight loss projected at 68 weeks in Phase 2 modeling Dosing schedule / Once weekly subcutaneous injection (doses 1 mg through 12 mg tested) Comparator benchmark / Semaglutide 2.4 mg: 14.9% at 68 weeks (STEP-1, N=1,961) Comparator benchmark / Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1, N=2,539) Primary side effects / Nausea, vomiting, diarrhea, constipation (dose-dependent) Phase 3 status / Phase 3 program (TRIUMPH trials) enrolling as of 2024 Manufacturer / Eli Lilly and Company What Is Retatrutide
What Clinical Data Shows Joint pain is not listed as a common side effect in Wegovy's original clinical trials, yet patient reports on social media and in medical forums have raised concerns
Second week I noticed the morning stiffness was less severe
Address Correspondence to: Maria Ukhanova, MD, PhD, UTHealth Houston School of Public Health, Center for Health Care Data, 1200 Pressler St, Houston, TX 77030
Combination with premix insulin 12 oral antidiabetic medicinal products On week 30 of the trial (see Subsection Assessment of Effect on CVS) a subset of 867 patients on therapy with premixed insulin (with or without 12 oral antidiabetic medicinal products) was evaluated
British Journal of Sports Medicine, 59(8), e109104